nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—ACVR1—pes—psoriatic arthritis	0.0342	0.148	CbGeAlD
Crizotinib—BMP2K—synovial membrane of synovial joint—psoriatic arthritis	0.0163	0.0708	CbGeAlD
Crizotinib—RIPK2—synovial membrane of synovial joint—psoriatic arthritis	0.0157	0.0678	CbGeAlD
Crizotinib—ABCB1—Methylprednisolone—psoriatic arthritis	0.0145	0.152	CbGbCtD
Crizotinib—ROS1—tendon—psoriatic arthritis	0.01	0.0434	CbGeAlD
Crizotinib—ABCB1—Betamethasone—psoriatic arthritis	0.00941	0.0989	CbGbCtD
Crizotinib—ABCB1—Prednisolone—psoriatic arthritis	0.00928	0.0976	CbGbCtD
Crizotinib—ABCB1—Prednisone—psoriatic arthritis	0.00877	0.0921	CbGbCtD
Crizotinib—CYP3A4—Methylprednisolone—psoriatic arthritis	0.00867	0.0911	CbGbCtD
Crizotinib—Interstitial lung disease—Auranofin—psoriatic arthritis	0.00853	0.0351	CcSEcCtD
Crizotinib—MUSK—tendon—psoriatic arthritis	0.00852	0.0369	CbGeAlD
Crizotinib—CYP3A5—Dexamethasone—psoriatic arthritis	0.00841	0.0884	CbGbCtD
Crizotinib—Vitreous floaters—Dexamethasone—psoriatic arthritis	0.00707	0.0292	CcSEcCtD
Crizotinib—Vitreous floaters—Betamethasone—psoriatic arthritis	0.00707	0.0292	CcSEcCtD
Crizotinib—CYP3A4—Triamcinolone—psoriatic arthritis	0.00657	0.0691	CbGbCtD
Crizotinib—CYP3A4—Betamethasone—psoriatic arthritis	0.00564	0.0592	CbGbCtD
Crizotinib—CYP3A4—Prednisolone—psoriatic arthritis	0.00556	0.0585	CbGbCtD
Crizotinib—ABCB1—Dexamethasone—psoriatic arthritis	0.00547	0.0575	CbGbCtD
Crizotinib—CYP3A4—Prednisone—psoriatic arthritis	0.00525	0.0552	CbGbCtD
Crizotinib—Photopsia—Betamethasone—psoriatic arthritis	0.00505	0.0208	CcSEcCtD
Crizotinib—Photopsia—Dexamethasone—psoriatic arthritis	0.00505	0.0208	CcSEcCtD
Crizotinib—MET—skin of body—psoriatic arthritis	0.00495	0.0214	CbGeAlD
Crizotinib—LIMK1—tendon—psoriatic arthritis	0.00447	0.0194	CbGeAlD
Crizotinib—ABCB1—Methotrexate—psoriatic arthritis	0.0044	0.0462	CbGbCtD
Crizotinib—TYRO3—skin of body—psoriatic arthritis	0.00405	0.0175	CbGeAlD
Crizotinib—MAPK7—tendon—psoriatic arthritis	0.00403	0.0174	CbGeAlD
Crizotinib—FES—tendon—psoriatic arthritis	0.00399	0.0173	CbGeAlD
Crizotinib—IGF1R—skin of body—psoriatic arthritis	0.00389	0.0169	CbGeAlD
Crizotinib—MET—tendon—psoriatic arthritis	0.00377	0.0163	CbGeAlD
Crizotinib—TAOK2—tendon—psoriatic arthritis	0.00362	0.0157	CbGeAlD
Crizotinib—Neutropenia—Auranofin—psoriatic arthritis	0.00354	0.0146	CcSEcCtD
Crizotinib—Weight decreased—Auranofin—psoriatic arthritis	0.00343	0.0141	CcSEcCtD
Crizotinib—STK35—skin of body—psoriatic arthritis	0.00338	0.0146	CbGeAlD
Crizotinib—Neuropathy peripheral—Auranofin—psoriatic arthritis	0.00331	0.0136	CcSEcCtD
Crizotinib—DCLK1—tendon—psoriatic arthritis	0.0033	0.0143	CbGeAlD
Crizotinib—CYP3A4—Dexamethasone—psoriatic arthritis	0.00328	0.0345	CbGbCtD
Crizotinib—RIPK2—skin of body—psoriatic arthritis	0.00311	0.0135	CbGeAlD
Crizotinib—FER—tendon—psoriatic arthritis	0.00308	0.0134	CbGeAlD
Crizotinib—TNK1—tendon—psoriatic arthritis	0.00305	0.0132	CbGeAlD
Crizotinib—MAP4K1—tendon—psoriatic arthritis	0.00302	0.0131	CbGeAlD
Crizotinib—MAP4K2—tendon—psoriatic arthritis	0.00292	0.0127	CbGeAlD
Crizotinib—Visual impairment—Auranofin—psoriatic arthritis	0.00292	0.012	CcSEcCtD
Crizotinib—PTK2—skin of body—psoriatic arthritis	0.00289	0.0125	CbGeAlD
Crizotinib—STK3—tendon—psoriatic arthritis	0.00288	0.0125	CbGeAlD
Crizotinib—TYK2—skin of body—psoriatic arthritis	0.00287	0.0124	CbGeAlD
Crizotinib—Eye disorder—Auranofin—psoriatic arthritis	0.00283	0.0117	CcSEcCtD
Crizotinib—AURKA—tendon—psoriatic arthritis	0.00281	0.0122	CbGeAlD
Crizotinib—TESK1—tendon—psoriatic arthritis	0.00279	0.0121	CbGeAlD
Crizotinib—AXL—skin of body—psoriatic arthritis	0.00275	0.0119	CbGeAlD
Crizotinib—Lymphopenia—Prednisone—psoriatic arthritis	0.00273	0.0113	CcSEcCtD
Crizotinib—MERTK—tendon—psoriatic arthritis	0.00271	0.0117	CbGeAlD
Crizotinib—Visual acuity reduced—Betamethasone—psoriatic arthritis	0.0027	0.0111	CcSEcCtD
Crizotinib—Visual acuity reduced—Dexamethasone—psoriatic arthritis	0.0027	0.0111	CcSEcCtD
Crizotinib—ACVR1—tendon—psoriatic arthritis	0.00262	0.0114	CbGeAlD
Crizotinib—MAP3K12—tendon—psoriatic arthritis	0.00262	0.0114	CbGeAlD
Crizotinib—JAK2—skin of body—psoriatic arthritis	0.00261	0.0113	CbGeAlD
Crizotinib—Dysgeusia—Auranofin—psoriatic arthritis	0.00258	0.0106	CcSEcCtD
Crizotinib—STK35—tendon—psoriatic arthritis	0.00257	0.0111	CbGeAlD
Crizotinib—MAP3K3—skin of body—psoriatic arthritis	0.00252	0.0109	CbGeAlD
Crizotinib—ABL2—tendon—psoriatic arthritis	0.0025	0.0108	CbGeAlD
Crizotinib—BMP2K—tendon—psoriatic arthritis	0.00247	0.0107	CbGeAlD
Crizotinib—Anaemia—Auranofin—psoriatic arthritis	0.00244	0.0101	CcSEcCtD
Crizotinib—Abscess—Prednisolone—psoriatic arthritis	0.00243	0.01	CcSEcCtD
Crizotinib—EPHB6—skin of body—psoriatic arthritis	0.00241	0.0104	CbGeAlD
Crizotinib—PTK2B—tendon—psoriatic arthritis	0.00239	0.0103	CbGeAlD
Crizotinib—RIPK2—tendon—psoriatic arthritis	0.00237	0.0103	CbGeAlD
Crizotinib—Leukopenia—Auranofin—psoriatic arthritis	0.00236	0.00973	CcSEcCtD
Crizotinib—Febrile neutropenia—Prednisone—psoriatic arthritis	0.00232	0.00958	CcSEcCtD
Crizotinib—EPHA4—tendon—psoriatic arthritis	0.00229	0.00992	CbGeAlD
Crizotinib—Abscess—Triamcinolone—psoriatic arthritis	0.00224	0.00922	CcSEcCtD
Crizotinib—SRC—skin of body—psoriatic arthritis	0.00224	0.00968	CbGeAlD
Crizotinib—Abscess—Methylprednisolone—psoriatic arthritis	0.00223	0.0092	CcSEcCtD
Crizotinib—TBK1—tendon—psoriatic arthritis	0.0022	0.00952	CbGeAlD
Crizotinib—PTK2—tendon—psoriatic arthritis	0.0022	0.00952	CbGeAlD
Crizotinib—TYK2—tendon—psoriatic arthritis	0.00218	0.00946	CbGeAlD
Crizotinib—IRAK1—tendon—psoriatic arthritis	0.00216	0.00934	CbGeAlD
Crizotinib—RPS6KB1—tendon—psoriatic arthritis	0.00212	0.00916	CbGeAlD
Crizotinib—FGR—tendon—psoriatic arthritis	0.0021	0.00911	CbGeAlD
Crizotinib—AXL—tendon—psoriatic arthritis	0.00209	0.00907	CbGeAlD
Crizotinib—Abscess—Betamethasone—psoriatic arthritis	0.00203	0.00837	CcSEcCtD
Crizotinib—Abscess—Dexamethasone—psoriatic arthritis	0.00203	0.00837	CcSEcCtD
Crizotinib—SLK—tendon—psoriatic arthritis	0.00202	0.00873	CbGeAlD
Crizotinib—CSF1R—skin of body—psoriatic arthritis	0.00201	0.00869	CbGeAlD
Crizotinib—EPHB4—tendon—psoriatic arthritis	0.002	0.00867	CbGeAlD
Crizotinib—JAK2—tendon—psoriatic arthritis	0.00199	0.00861	CbGeAlD
Crizotinib—EPHA2—tendon—psoriatic arthritis	0.00196	0.0085	CbGeAlD
Crizotinib—Febrile neutropenia—Methotrexate—psoriatic arthritis	0.00194	0.00801	CcSEcCtD
Crizotinib—MAP4K5—tendon—psoriatic arthritis	0.00192	0.0083	CbGeAlD
Crizotinib—TEK—tendon—psoriatic arthritis	0.00192	0.0083	CbGeAlD
Crizotinib—MAP3K3—tendon—psoriatic arthritis	0.00192	0.0083	CbGeAlD
Crizotinib—Dyspepsia—Auranofin—psoriatic arthritis	0.0019	0.00781	CcSEcCtD
Crizotinib—Decreased appetite—Auranofin—psoriatic arthritis	0.00187	0.00772	CcSEcCtD
Crizotinib—Constipation—Auranofin—psoriatic arthritis	0.00184	0.00759	CcSEcCtD
Crizotinib—EPHB6—tendon—psoriatic arthritis	0.00183	0.00793	CbGeAlD
Crizotinib—Fluid retention—Prednisolone—psoriatic arthritis	0.00183	0.00753	CcSEcCtD
Crizotinib—Neuropathy—Prednisolone—psoriatic arthritis	0.00181	0.00745	CcSEcCtD
Crizotinib—YES1—tendon—psoriatic arthritis	0.00177	0.00766	CbGeAlD
Crizotinib—Abscess—Prednisone—psoriatic arthritis	0.00177	0.00728	CcSEcCtD
Crizotinib—STK10—tendon—psoriatic arthritis	0.00175	0.00759	CbGeAlD
Crizotinib—TAOK3—tendon—psoriatic arthritis	0.00175	0.00756	CbGeAlD
Crizotinib—Burning sensation—Methotrexate—psoriatic arthritis	0.00168	0.00693	CcSEcCtD
Crizotinib—Fluid retention—Triamcinolone—psoriatic arthritis	0.00168	0.00693	CcSEcCtD
Crizotinib—Fluid retention—Methylprednisolone—psoriatic arthritis	0.00168	0.00691	CcSEcCtD
Crizotinib—Neuropathy—Triamcinolone—psoriatic arthritis	0.00166	0.00685	CcSEcCtD
Crizotinib—Neuropathy—Methylprednisolone—psoriatic arthritis	0.00166	0.00683	CcSEcCtD
Crizotinib—Interstitial lung disease—Methotrexate—psoriatic arthritis	0.00165	0.00681	CcSEcCtD
Crizotinib—ABL1—skin of body—psoriatic arthritis	0.00159	0.00687	CbGeAlD
Crizotinib—CSF1R—tendon—psoriatic arthritis	0.00153	0.00662	CbGeAlD
Crizotinib—Fluid retention—Betamethasone—psoriatic arthritis	0.00152	0.00628	CcSEcCtD
Crizotinib—Fluid retention—Dexamethasone—psoriatic arthritis	0.00152	0.00628	CcSEcCtD
Crizotinib—Hepatotoxicity—Methotrexate—psoriatic arthritis	0.00151	0.00624	CcSEcCtD
Crizotinib—Neuropathy—Betamethasone—psoriatic arthritis	0.00151	0.00621	CcSEcCtD
Crizotinib—Neuropathy—Dexamethasone—psoriatic arthritis	0.00151	0.00621	CcSEcCtD
Crizotinib—Abscess—Methotrexate—psoriatic arthritis	0.00148	0.00609	CcSEcCtD
Crizotinib—Visual disturbance—Prednisolone—psoriatic arthritis	0.00147	0.00608	CcSEcCtD
Crizotinib—Blood alkaline phosphatase increased—Methylprednisolone—psoriatic arthritis	0.00147	0.00607	CcSEcCtD
Crizotinib—Diarrhoea—Auranofin—psoriatic arthritis	0.00147	0.00607	CcSEcCtD
Crizotinib—Vomiting—Auranofin—psoriatic arthritis	0.00137	0.00564	CcSEcCtD
Crizotinib—Rash—Auranofin—psoriatic arthritis	0.00136	0.0056	CcSEcCtD
Crizotinib—Dermatitis—Auranofin—psoriatic arthritis	0.00136	0.00559	CcSEcCtD
Crizotinib—Fluid retention—Prednisone—psoriatic arthritis	0.00133	0.00547	CcSEcCtD
Crizotinib—Neuropathy—Prednisone—psoriatic arthritis	0.00131	0.00541	CcSEcCtD
Crizotinib—Nausea—Auranofin—psoriatic arthritis	0.00128	0.00527	CcSEcCtD
Crizotinib—Muscular weakness—Prednisolone—psoriatic arthritis	0.00123	0.00508	CcSEcCtD
Crizotinib—Visual disturbance—Dexamethasone—psoriatic arthritis	0.00123	0.00507	CcSEcCtD
Crizotinib—Visual disturbance—Betamethasone—psoriatic arthritis	0.00123	0.00507	CcSEcCtD
Crizotinib—Sepsis—Prednisone—psoriatic arthritis	0.00121	0.005	CcSEcCtD
Crizotinib—ABL1—tendon—psoriatic arthritis	0.00121	0.00523	CbGeAlD
Crizotinib—Respiratory failure—Methotrexate—psoriatic arthritis	0.00119	0.00491	CcSEcCtD
Crizotinib—Pulmonary embolism—Methotrexate—psoriatic arthritis	0.00117	0.00482	CcSEcCtD
Crizotinib—Muscular weakness—Triamcinolone—psoriatic arthritis	0.00113	0.00467	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Methylprednisolone—psoriatic arthritis	0.00113	0.00466	CcSEcCtD
Crizotinib—Muscular weakness—Methylprednisolone—psoriatic arthritis	0.00113	0.00466	CcSEcCtD
Crizotinib—Hypokalaemia—Betamethasone—psoriatic arthritis	0.00106	0.00437	CcSEcCtD
Crizotinib—Hypokalaemia—Dexamethasone—psoriatic arthritis	0.00106	0.00437	CcSEcCtD
Crizotinib—Neuropathy peripheral—Prednisolone—psoriatic arthritis	0.00105	0.00435	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Triamcinolone—psoriatic arthritis	0.00103	0.00425	CcSEcCtD
Crizotinib—Muscular weakness—Dexamethasone—psoriatic arthritis	0.00103	0.00424	CcSEcCtD
Crizotinib—Muscular weakness—Betamethasone—psoriatic arthritis	0.00103	0.00424	CcSEcCtD
Crizotinib—Sepsis—Methotrexate—psoriatic arthritis	0.00101	0.00418	CcSEcCtD
Crizotinib—Infestation—Methylprednisolone—psoriatic arthritis	0.000988	0.00407	CcSEcCtD
Crizotinib—Infestation NOS—Methylprednisolone—psoriatic arthritis	0.000988	0.00407	CcSEcCtD
Crizotinib—Bradycardia—Prednisolone—psoriatic arthritis	0.000984	0.00406	CcSEcCtD
Crizotinib—Face oedema—Prednisone—psoriatic arthritis	0.00098	0.00404	CcSEcCtD
Crizotinib—Neuropathy peripheral—Triamcinolone—psoriatic arthritis	0.00097	0.004	CcSEcCtD
Crizotinib—Neuropathy peripheral—Methylprednisolone—psoriatic arthritis	0.000968	0.00399	CcSEcCtD
Crizotinib—Hepatic failure—Methotrexate—psoriatic arthritis	0.000944	0.00389	CcSEcCtD
Crizotinib—Visual impairment—Prednisolone—psoriatic arthritis	0.000931	0.00384	CcSEcCtD
Crizotinib—Hypokalaemia—Prednisone—psoriatic arthritis	0.000924	0.00381	CcSEcCtD
Crizotinib—Weight decreased—Betamethasone—psoriatic arthritis	0.000911	0.00376	CcSEcCtD
Crizotinib—Weight decreased—Dexamethasone—psoriatic arthritis	0.000911	0.00376	CcSEcCtD
Crizotinib—Bradycardia—Triamcinolone—psoriatic arthritis	0.000905	0.00373	CcSEcCtD
Crizotinib—Bradycardia—Methylprednisolone—psoriatic arthritis	0.000903	0.00372	CcSEcCtD
Crizotinib—Muscular weakness—Prednisone—psoriatic arthritis	0.000895	0.00369	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Prednisone—psoriatic arthritis	0.000895	0.00369	CcSEcCtD
Crizotinib—Visual disturbance—Methotrexate—psoriatic arthritis	0.000895	0.00369	CcSEcCtD
Crizotinib—Neuropathy peripheral—Dexamethasone—psoriatic arthritis	0.00088	0.00363	CcSEcCtD
Crizotinib—Neuropathy peripheral—Betamethasone—psoriatic arthritis	0.00088	0.00363	CcSEcCtD
Crizotinib—Arrhythmia—Prednisolone—psoriatic arthritis	0.000863	0.00356	CcSEcCtD
Crizotinib—ACVR1—Betamethasone—Methylprednisolone—psoriatic arthritis	0.000859	0.064	CbGdCrCtD
Crizotinib—ACVR1—Dexamethasone—Methylprednisolone—psoriatic arthritis	0.000859	0.064	CbGdCrCtD
Crizotinib—Visual impairment—Methylprednisolone—psoriatic arthritis	0.000854	0.00352	CcSEcCtD
Crizotinib—ACVR1—Betamethasone—Dexamethasone—psoriatic arthritis	0.000845	0.063	CbGdCrCtD
Crizotinib—ACVR1—Dexamethasone—Betamethasone—psoriatic arthritis	0.000845	0.063	CbGdCrCtD
Crizotinib—Eye disorder—Methylprednisolone—psoriatic arthritis	0.000828	0.00342	CcSEcCtD
Crizotinib—ACVR1—Betamethasone—Triamcinolone—psoriatic arthritis	0.000826	0.0616	CbGdCrCtD
Crizotinib—ACVR1—Dexamethasone—Triamcinolone—psoriatic arthritis	0.000826	0.0616	CbGdCrCtD
Crizotinib—Cardiac disorder—Methylprednisolone—psoriatic arthritis	0.000823	0.00339	CcSEcCtD
Crizotinib—Bradycardia—Dexamethasone—psoriatic arthritis	0.000821	0.00338	CcSEcCtD
Crizotinib—Bradycardia—Betamethasone—psoriatic arthritis	0.000821	0.00338	CcSEcCtD
Crizotinib—Neutropenia—Prednisone—psoriatic arthritis	0.00082	0.00338	CcSEcCtD
Crizotinib—Mediastinal disorder—Methylprednisolone—psoriatic arthritis	0.000799	0.00329	CcSEcCtD
Crizotinib—Arrhythmia—Triamcinolone—psoriatic arthritis	0.000794	0.00327	CcSEcCtD
Crizotinib—Weight decreased—Prednisone—psoriatic arthritis	0.000794	0.00327	CcSEcCtD
Crizotinib—Vision blurred—Prednisolone—psoriatic arthritis	0.000793	0.00327	CcSEcCtD
Crizotinib—Arrhythmia—Methylprednisolone—psoriatic arthritis	0.000792	0.00327	CcSEcCtD
Crizotinib—ACVR1—Betamethasone—Prednisone—psoriatic arthritis	0.000784	0.0584	CbGdCrCtD
Crizotinib—ACVR1—Dexamethasone—Prednisone—psoriatic arthritis	0.000784	0.0584	CbGdCrCtD
Crizotinib—Visual impairment—Betamethasone—psoriatic arthritis	0.000777	0.0032	CcSEcCtD
Crizotinib—Visual impairment—Dexamethasone—psoriatic arthritis	0.000777	0.0032	CcSEcCtD
Crizotinib—Malnutrition—Methylprednisolone—psoriatic arthritis	0.000772	0.00318	CcSEcCtD
Crizotinib—Neuropathy peripheral—Prednisone—psoriatic arthritis	0.000767	0.00316	CcSEcCtD
Crizotinib—ACVR1—Dexamethasone—Prednisolone—psoriatic arthritis	0.000765	0.057	CbGdCrCtD
Crizotinib—ACVR1—Betamethasone—Prednisolone—psoriatic arthritis	0.000765	0.057	CbGdCrCtD
Crizotinib—Dysgeusia—Triamcinolone—psoriatic arthritis	0.000757	0.00312	CcSEcCtD
Crizotinib—Syncope—Prednisolone—psoriatic arthritis	0.000754	0.00311	CcSEcCtD
Crizotinib—Eye disorder—Dexamethasone—psoriatic arthritis	0.000753	0.00311	CcSEcCtD
Crizotinib—Eye disorder—Betamethasone—psoriatic arthritis	0.000753	0.00311	CcSEcCtD
Crizotinib—Loss of consciousness—Prednisolone—psoriatic arthritis	0.000739	0.00305	CcSEcCtD
Crizotinib—Arrhythmia—Betamethasone—psoriatic arthritis	0.00072	0.00297	CcSEcCtD
Crizotinib—Arrhythmia—Dexamethasone—psoriatic arthritis	0.00072	0.00297	CcSEcCtD
Crizotinib—Bradycardia—Prednisone—psoriatic arthritis	0.000715	0.00295	CcSEcCtD
Crizotinib—Syncope—Triamcinolone—psoriatic arthritis	0.000694	0.00286	CcSEcCtD
Crizotinib—Syncope—Methylprednisolone—psoriatic arthritis	0.000692	0.00285	CcSEcCtD
Crizotinib—Oedema—Prednisolone—psoriatic arthritis	0.000686	0.00283	CcSEcCtD
Crizotinib—Neutropenia—Methotrexate—psoriatic arthritis	0.000685	0.00283	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Methotrexate—psoriatic arthritis	0.000681	0.00281	CcSEcCtD
Crizotinib—Loss of consciousness—Triamcinolone—psoriatic arthritis	0.00068	0.0028	CcSEcCtD
Crizotinib—Loss of consciousness—Methylprednisolone—psoriatic arthritis	0.000678	0.0028	CcSEcCtD
Crizotinib—Shock—Prednisolone—psoriatic arthritis	0.000675	0.00278	CcSEcCtD
Crizotinib—Pneumonia—Methotrexate—psoriatic arthritis	0.000657	0.00271	CcSEcCtD
Crizotinib—Eye disorder—Prednisone—psoriatic arthritis	0.000656	0.00271	CcSEcCtD
Crizotinib—Infestation NOS—Methotrexate—psoriatic arthritis	0.000654	0.00269	CcSEcCtD
Crizotinib—Infestation—Methotrexate—psoriatic arthritis	0.000654	0.00269	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—psoriatic arthritis	0.000653	0.00269	CcSEcCtD
Crizotinib—Oedema—Triamcinolone—psoriatic arthritis	0.000631	0.0026	CcSEcCtD
Crizotinib—Syncope—Betamethasone—psoriatic arthritis	0.000629	0.00259	CcSEcCtD
Crizotinib—Syncope—Dexamethasone—psoriatic arthritis	0.000629	0.00259	CcSEcCtD
Crizotinib—Arrhythmia—Prednisone—psoriatic arthritis	0.000627	0.00259	CcSEcCtD
Crizotinib—Infection—Triamcinolone—psoriatic arthritis	0.000627	0.00259	CcSEcCtD
Crizotinib—Infection—Methylprednisolone—psoriatic arthritis	0.000626	0.00258	CcSEcCtD
Crizotinib—Shock—Triamcinolone—psoriatic arthritis	0.000621	0.00256	CcSEcCtD
Crizotinib—Shock—Methylprednisolone—psoriatic arthritis	0.00062	0.00255	CcSEcCtD
Crizotinib—Hepatobiliary disease—Methotrexate—psoriatic arthritis	0.000618	0.00255	CcSEcCtD
Crizotinib—Nervous system disorder—Methylprednisolone—psoriatic arthritis	0.000618	0.00255	CcSEcCtD
Crizotinib—Loss of consciousness—Dexamethasone—psoriatic arthritis	0.000617	0.00254	CcSEcCtD
Crizotinib—Loss of consciousness—Betamethasone—psoriatic arthritis	0.000617	0.00254	CcSEcCtD
Crizotinib—Paraesthesia—Prednisolone—psoriatic arthritis	0.000616	0.00254	CcSEcCtD
Crizotinib—Skin disorder—Methylprednisolone—psoriatic arthritis	0.000612	0.00252	CcSEcCtD
Crizotinib—Malnutrition—Prednisone—psoriatic arthritis	0.000611	0.00252	CcSEcCtD
Crizotinib—Urinary tract disorder—Methotrexate—psoriatic arthritis	0.000579	0.00239	CcSEcCtD
Crizotinib—Vision blurred—Prednisone—psoriatic arthritis	0.000576	0.00237	CcSEcCtD
Crizotinib—Urethral disorder—Methotrexate—psoriatic arthritis	0.000575	0.00237	CcSEcCtD
Crizotinib—Oedema—Dexamethasone—psoriatic arthritis	0.000573	0.00236	CcSEcCtD
Crizotinib—Oedema—Betamethasone—psoriatic arthritis	0.000573	0.00236	CcSEcCtD
Crizotinib—Infection—Betamethasone—psoriatic arthritis	0.000569	0.00235	CcSEcCtD
Crizotinib—Infection—Dexamethasone—psoriatic arthritis	0.000569	0.00235	CcSEcCtD
Crizotinib—Paraesthesia—Triamcinolone—psoriatic arthritis	0.000567	0.00234	CcSEcCtD
Crizotinib—Paraesthesia—Methylprednisolone—psoriatic arthritis	0.000566	0.00233	CcSEcCtD
Crizotinib—Visual impairment—Methotrexate—psoriatic arthritis	0.000565	0.00233	CcSEcCtD
Crizotinib—Anaemia—Prednisone—psoriatic arthritis	0.000565	0.00233	CcSEcCtD
Crizotinib—Shock—Dexamethasone—psoriatic arthritis	0.000564	0.00232	CcSEcCtD
Crizotinib—Shock—Betamethasone—psoriatic arthritis	0.000564	0.00232	CcSEcCtD
Crizotinib—Dyspnoea—Triamcinolone—psoriatic arthritis	0.000563	0.00232	CcSEcCtD
Crizotinib—Nervous system disorder—Betamethasone—psoriatic arthritis	0.000562	0.00232	CcSEcCtD
Crizotinib—Nervous system disorder—Dexamethasone—psoriatic arthritis	0.000562	0.00232	CcSEcCtD
Crizotinib—Dyspepsia—Triamcinolone—psoriatic arthritis	0.000556	0.00229	CcSEcCtD
Crizotinib—Dyspepsia—Methylprednisolone—psoriatic arthritis	0.000554	0.00229	CcSEcCtD
Crizotinib—TESK1—Betamethasone—Methylprednisolone—psoriatic arthritis	0.000554	0.0413	CbGdCrCtD
Crizotinib—TESK1—Dexamethasone—Methylprednisolone—psoriatic arthritis	0.000554	0.0413	CbGdCrCtD
Crizotinib—Eye disorder—Methotrexate—psoriatic arthritis	0.000548	0.00226	CcSEcCtD
Crizotinib—Syncope—Prednisone—psoriatic arthritis	0.000548	0.00226	CcSEcCtD
Crizotinib—TESK1—Dexamethasone—Betamethasone—psoriatic arthritis	0.000545	0.0406	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Dexamethasone—psoriatic arthritis	0.000545	0.0406	CbGdCrCtD
Crizotinib—Cardiac disorder—Methotrexate—psoriatic arthritis	0.000545	0.00225	CcSEcCtD
Crizotinib—Fatigue—Triamcinolone—psoriatic arthritis	0.000544	0.00224	CcSEcCtD
Crizotinib—Fatigue—Methylprednisolone—psoriatic arthritis	0.000543	0.00224	CcSEcCtD
Crizotinib—Loss of consciousness—Prednisone—psoriatic arthritis	0.000537	0.00221	CcSEcCtD
Crizotinib—TESK1—Dexamethasone—Triamcinolone—psoriatic arthritis	0.000532	0.0397	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Triamcinolone—psoriatic arthritis	0.000532	0.0397	CbGdCrCtD
Crizotinib—Mediastinal disorder—Methotrexate—psoriatic arthritis	0.000529	0.00218	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriatic arthritis	0.000517	0.00213	CcSEcCtD
Crizotinib—Paraesthesia—Dexamethasone—psoriatic arthritis	0.000514	0.00212	CcSEcCtD
Crizotinib—Paraesthesia—Betamethasone—psoriatic arthritis	0.000514	0.00212	CcSEcCtD
Crizotinib—Malnutrition—Methotrexate—psoriatic arthritis	0.000511	0.00211	CcSEcCtD
Crizotinib—TESK1—Betamethasone—Prednisone—psoriatic arthritis	0.000505	0.0377	CbGdCrCtD
Crizotinib—TESK1—Dexamethasone—Prednisone—psoriatic arthritis	0.000505	0.0377	CbGdCrCtD
Crizotinib—Dyspepsia—Dexamethasone—psoriatic arthritis	0.000504	0.00208	CcSEcCtD
Crizotinib—Dyspepsia—Betamethasone—psoriatic arthritis	0.000504	0.00208	CcSEcCtD
Crizotinib—Dysgeusia—Methotrexate—psoriatic arthritis	0.0005	0.00206	CcSEcCtD
Crizotinib—Body temperature increased—Triamcinolone—psoriatic arthritis	0.000499	0.00206	CcSEcCtD
Crizotinib—Oedema—Prednisone—psoriatic arthritis	0.000499	0.00206	CcSEcCtD
Crizotinib—Decreased appetite—Dexamethasone—psoriatic arthritis	0.000498	0.00205	CcSEcCtD
Crizotinib—Decreased appetite—Betamethasone—psoriatic arthritis	0.000498	0.00205	CcSEcCtD
Crizotinib—Infection—Prednisone—psoriatic arthritis	0.000496	0.00204	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	0.000494	0.00204	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	0.000494	0.00204	CcSEcCtD
Crizotinib—Fatigue—Dexamethasone—psoriatic arthritis	0.000494	0.00204	CcSEcCtD
Crizotinib—Fatigue—Betamethasone—psoriatic arthritis	0.000494	0.00204	CcSEcCtD
Crizotinib—TESK1—Dexamethasone—Prednisolone—psoriatic arthritis	0.000493	0.0368	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Prednisolone—psoriatic arthritis	0.000493	0.0368	CbGdCrCtD
Crizotinib—Shock—Prednisone—psoriatic arthritis	0.000491	0.00202	CcSEcCtD
Crizotinib—Nervous system disorder—Prednisone—psoriatic arthritis	0.000489	0.00202	CcSEcCtD
Crizotinib—Skin disorder—Prednisone—psoriatic arthritis	0.000485	0.002	CcSEcCtD
Crizotinib—Vision blurred—Methotrexate—psoriatic arthritis	0.000481	0.00198	CcSEcCtD
Crizotinib—Anaemia—Methotrexate—psoriatic arthritis	0.000472	0.00195	CcSEcCtD
Crizotinib—Leukopenia—Methotrexate—psoriatic arthritis	0.000457	0.00188	CcSEcCtD
Crizotinib—Dizziness—Prednisolone—psoriatic arthritis	0.000454	0.00187	CcSEcCtD
Crizotinib—Asthenia—Triamcinolone—psoriatic arthritis	0.000453	0.00187	CcSEcCtD
Crizotinib—Body temperature increased—Dexamethasone—psoriatic arthritis	0.000453	0.00187	CcSEcCtD
Crizotinib—Body temperature increased—Betamethasone—psoriatic arthritis	0.000453	0.00187	CcSEcCtD
Crizotinib—Asthenia—Methylprednisolone—psoriatic arthritis	0.000452	0.00186	CcSEcCtD
Crizotinib—Paraesthesia—Prednisone—psoriatic arthritis	0.000448	0.00185	CcSEcCtD
Crizotinib—Dyspepsia—Prednisone—psoriatic arthritis	0.000439	0.00181	CcSEcCtD
Crizotinib—Decreased appetite—Prednisone—psoriatic arthritis	0.000434	0.00179	CcSEcCtD
Crizotinib—Rash—Prednisolone—psoriatic arthritis	0.000433	0.00178	CcSEcCtD
Crizotinib—Dermatitis—Prednisolone—psoriatic arthritis	0.000432	0.00178	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriatic arthritis	0.000432	0.00178	CcSEcCtD
Crizotinib—Diarrhoea—Methylprednisolone—psoriatic arthritis	0.000431	0.00178	CcSEcCtD
Crizotinib—Fatigue—Prednisone—psoriatic arthritis	0.00043	0.00177	CcSEcCtD
Crizotinib—Constipation—Prednisone—psoriatic arthritis	0.000427	0.00176	CcSEcCtD
Crizotinib—Dizziness—Triamcinolone—psoriatic arthritis	0.000417	0.00172	CcSEcCtD
Crizotinib—Dizziness—Methylprednisolone—psoriatic arthritis	0.000417	0.00172	CcSEcCtD
Crizotinib—Infection—Methotrexate—psoriatic arthritis	0.000414	0.00171	CcSEcCtD
Crizotinib—Asthenia—Betamethasone—psoriatic arthritis	0.000411	0.00169	CcSEcCtD
Crizotinib—Asthenia—Dexamethasone—psoriatic arthritis	0.000411	0.00169	CcSEcCtD
Crizotinib—Nervous system disorder—Methotrexate—psoriatic arthritis	0.000409	0.00169	CcSEcCtD
Crizotinib—Nausea—Prednisolone—psoriatic arthritis	0.000408	0.00168	CcSEcCtD
Crizotinib—Skin disorder—Methotrexate—psoriatic arthritis	0.000405	0.00167	CcSEcCtD
Crizotinib—Vomiting—Triamcinolone—psoriatic arthritis	0.000401	0.00165	CcSEcCtD
Crizotinib—Vomiting—Methylprednisolone—psoriatic arthritis	0.0004	0.00165	CcSEcCtD
Crizotinib—Rash—Triamcinolone—psoriatic arthritis	0.000398	0.00164	CcSEcCtD
Crizotinib—Dermatitis—Triamcinolone—psoriatic arthritis	0.000398	0.00164	CcSEcCtD
Crizotinib—Rash—Methylprednisolone—psoriatic arthritis	0.000397	0.00164	CcSEcCtD
Crizotinib—Dermatitis—Methylprednisolone—psoriatic arthritis	0.000397	0.00164	CcSEcCtD
Crizotinib—Body temperature increased—Prednisone—psoriatic arthritis	0.000394	0.00163	CcSEcCtD
Crizotinib—Diarrhoea—Betamethasone—psoriatic arthritis	0.000392	0.00162	CcSEcCtD
Crizotinib—Diarrhoea—Dexamethasone—psoriatic arthritis	0.000392	0.00162	CcSEcCtD
Crizotinib—Dizziness—Dexamethasone—psoriatic arthritis	0.000379	0.00156	CcSEcCtD
Crizotinib—Dizziness—Betamethasone—psoriatic arthritis	0.000379	0.00156	CcSEcCtD
Crizotinib—Nausea—Triamcinolone—psoriatic arthritis	0.000375	0.00155	CcSEcCtD
Crizotinib—Paraesthesia—Methotrexate—psoriatic arthritis	0.000374	0.00154	CcSEcCtD
Crizotinib—Nausea—Methylprednisolone—psoriatic arthritis	0.000374	0.00154	CcSEcCtD
Crizotinib—Dyspnoea—Methotrexate—psoriatic arthritis	0.000372	0.00153	CcSEcCtD
Crizotinib—Dyspepsia—Methotrexate—psoriatic arthritis	0.000367	0.00151	CcSEcCtD
Crizotinib—Vomiting—Dexamethasone—psoriatic arthritis	0.000364	0.0015	CcSEcCtD
Crizotinib—Vomiting—Betamethasone—psoriatic arthritis	0.000364	0.0015	CcSEcCtD
Crizotinib—Decreased appetite—Methotrexate—psoriatic arthritis	0.000362	0.00149	CcSEcCtD
Crizotinib—Rash—Betamethasone—psoriatic arthritis	0.000361	0.00149	CcSEcCtD
Crizotinib—Rash—Dexamethasone—psoriatic arthritis	0.000361	0.00149	CcSEcCtD
Crizotinib—Dermatitis—Betamethasone—psoriatic arthritis	0.000361	0.00149	CcSEcCtD
Crizotinib—Dermatitis—Dexamethasone—psoriatic arthritis	0.000361	0.00149	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	0.00036	0.00148	CcSEcCtD
Crizotinib—Fatigue—Methotrexate—psoriatic arthritis	0.000359	0.00148	CcSEcCtD
Crizotinib—Asthenia—Prednisone—psoriatic arthritis	0.000358	0.00148	CcSEcCtD
Crizotinib—Diarrhoea—Prednisone—psoriatic arthritis	0.000341	0.00141	CcSEcCtD
Crizotinib—Nausea—Betamethasone—psoriatic arthritis	0.00034	0.0014	CcSEcCtD
Crizotinib—Nausea—Dexamethasone—psoriatic arthritis	0.00034	0.0014	CcSEcCtD
Crizotinib—Dizziness—Prednisone—psoriatic arthritis	0.00033	0.00136	CcSEcCtD
Crizotinib—Body temperature increased—Methotrexate—psoriatic arthritis	0.00033	0.00136	CcSEcCtD
Crizotinib—Vomiting—Prednisone—psoriatic arthritis	0.000317	0.00131	CcSEcCtD
Crizotinib—Rash—Prednisone—psoriatic arthritis	0.000315	0.0013	CcSEcCtD
Crizotinib—Dermatitis—Prednisone—psoriatic arthritis	0.000314	0.0013	CcSEcCtD
Crizotinib—Asthenia—Methotrexate—psoriatic arthritis	0.000299	0.00123	CcSEcCtD
Crizotinib—Nausea—Prednisone—psoriatic arthritis	0.000296	0.00122	CcSEcCtD
Crizotinib—Diarrhoea—Methotrexate—psoriatic arthritis	0.000285	0.00118	CcSEcCtD
Crizotinib—Dizziness—Methotrexate—psoriatic arthritis	0.000276	0.00114	CcSEcCtD
Crizotinib—Vomiting—Methotrexate—psoriatic arthritis	0.000265	0.00109	CcSEcCtD
Crizotinib—Rash—Methotrexate—psoriatic arthritis	0.000263	0.00108	CcSEcCtD
Crizotinib—Dermatitis—Methotrexate—psoriatic arthritis	0.000263	0.00108	CcSEcCtD
Crizotinib—Nausea—Methotrexate—psoriatic arthritis	0.000248	0.00102	CcSEcCtD
Crizotinib—TYK2—Immune System—MEFV—psoriatic arthritis	0.000228	0.000545	CbGpPWpGaD
Crizotinib—YES1—Adaptive Immune System—REL—psoriatic arthritis	0.000227	0.000543	CbGpPWpGaD
Crizotinib—EPHA7—Developmental Biology—TNF—psoriatic arthritis	0.000225	0.000539	CbGpPWpGaD
Crizotinib—MAPK7—Innate Immune System—CRP—psoriatic arthritis	0.000223	0.000534	CbGpPWpGaD
Crizotinib—LIMK1—Innate Immune System—CRP—psoriatic arthritis	0.000223	0.000534	CbGpPWpGaD
Crizotinib—TEK—Hemostasis—NOS2—psoriatic arthritis	0.000222	0.00053	CbGpPWpGaD
Crizotinib—TBK1—Immune System—REL—psoriatic arthritis	0.000221	0.000528	CbGpPWpGaD
Crizotinib—PTK2—Innate Immune System—HLA-C—psoriatic arthritis	0.000221	0.000528	CbGpPWpGaD
Crizotinib—IRAK1—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	0.000218	0.000521	CbGpPWpGaD
Crizotinib—YES1—Innate Immune System—HLA-C—psoriatic arthritis	0.000218	0.000521	CbGpPWpGaD
Crizotinib—TXK—Immune System—HLA-B—psoriatic arthritis	0.000213	0.00051	CbGpPWpGaD
Crizotinib—LYN—Cytokine Signaling in Immune system—NOD2—psoriatic arthritis	0.000213	0.000509	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—REL—psoriatic arthritis	0.000212	0.000506	CbGpPWpGaD
Crizotinib—TYK2—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	0.000211	0.000506	CbGpPWpGaD
Crizotinib—SRC—Aryl Hydrocarbon Receptor Pathway—TNF—psoriatic arthritis	0.000211	0.000504	CbGpPWpGaD
Crizotinib—SRC—Aryl Hydrocarbon Receptor—TNF—psoriatic arthritis	0.000211	0.000504	CbGpPWpGaD
Crizotinib—YES1—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000209	0.0005	CbGpPWpGaD
Crizotinib—RIPK2—Innate Immune System—NOD2—psoriatic arthritis	0.000207	0.000495	CbGpPWpGaD
Crizotinib—IRAK1—Innate Immune System—HLA-C—psoriatic arthritis	0.000206	0.000494	CbGpPWpGaD
Crizotinib—TBK1—Innate Immune System—HLA-B—psoriatic arthritis	0.000206	0.000494	CbGpPWpGaD
Crizotinib—TBK1—Immune System—HLA-C—psoriatic arthritis	0.000203	0.000486	CbGpPWpGaD
Crizotinib—JAK2—Interferon Signaling—HLA-DRB1—psoriatic arthritis	0.000203	0.000486	CbGpPWpGaD
Crizotinib—LCK—DAP12 interactions—HLA-B—psoriatic arthritis	0.000202	0.000484	CbGpPWpGaD
Crizotinib—ABCB1—Allograft Rejection—HLA-B—psoriatic arthritis	0.000202	0.000484	CbGpPWpGaD
Crizotinib—IKBKE—Immune System—NOD2—psoriatic arthritis	0.000201	0.000481	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—HLA-C—psoriatic arthritis	0.0002	0.000479	CbGpPWpGaD
Crizotinib—JAK3—Immune System—REL—psoriatic arthritis	0.0002	0.000478	CbGpPWpGaD
Crizotinib—JAK2—Cytokine Signaling in Immune system—NOD2—psoriatic arthritis	0.000199	0.000476	CbGpPWpGaD
Crizotinib—FGR—Innate Immune System—NOD2—psoriatic arthritis	0.000198	0.000474	CbGpPWpGaD
Crizotinib—IRAK1—Toll-like Receptor Signaling Pathway—TNF—psoriatic arthritis	0.000195	0.000467	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—HLA-C—psoriatic arthritis	0.000195	0.000466	CbGpPWpGaD
Crizotinib—YES1—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.000194	0.000465	CbGpPWpGaD
Crizotinib—TXK—Immune System—CRP—psoriatic arthritis	0.000189	0.000451	CbGpPWpGaD
Crizotinib—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriatic arthritis	0.000188	0.00045	CbGpPWpGaD
Crizotinib—LYN—Immune System—MEFV—psoriatic arthritis	0.000185	0.000442	CbGpPWpGaD
Crizotinib—IRAK1—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.000184	0.000441	CbGpPWpGaD
Crizotinib—ABL1—Immune System—MEFV—psoriatic arthritis	0.000184	0.00044	CbGpPWpGaD
Crizotinib—JAK3—Immune System—HLA-C—psoriatic arthritis	0.000184	0.00044	CbGpPWpGaD
Crizotinib—MAPK7—Immune System—NOD2—psoriatic arthritis	0.000183	0.000438	CbGpPWpGaD
Crizotinib—LIMK1—Immune System—NOD2—psoriatic arthritis	0.000183	0.000438	CbGpPWpGaD
Crizotinib—TBK1—Innate Immune System—CRP—psoriatic arthritis	0.000182	0.000436	CbGpPWpGaD
Crizotinib—TXK—Immune System—HLA-DRB1—psoriatic arthritis	0.000181	0.000432	CbGpPWpGaD
Crizotinib—TYK2—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.000179	0.000428	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—REL—psoriatic arthritis	0.000178	0.000426	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—REL—psoriatic arthritis	0.000175	0.00042	CbGpPWpGaD
Crizotinib—LCK—Cytokine Signaling in Immune system—NOD2—psoriatic arthritis	0.000174	0.000417	CbGpPWpGaD
Crizotinib—JAK2—Immune System—MEFV—psoriatic arthritis	0.000173	0.000413	CbGpPWpGaD
Crizotinib—BLK—Immune System—REL—psoriatic arthritis	0.000171	0.00041	CbGpPWpGaD
Crizotinib—ABCB1—Allograft Rejection—HLA-DRB1—psoriatic arthritis	0.000171	0.000409	CbGpPWpGaD
Crizotinib—LYN—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	0.000171	0.000409	CbGpPWpGaD
Crizotinib—FGR—Immune System—REL—psoriatic arthritis	0.000171	0.000408	CbGpPWpGaD
Crizotinib—ACVR1B—Developmental Biology—TNF—psoriatic arthritis	0.000171	0.000408	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—REL—psoriatic arthritis	0.000169	0.000405	CbGpPWpGaD
Crizotinib—NTRK1—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.000168	0.000403	CbGpPWpGaD
Crizotinib—JAK3—Hemostasis—NOS2—psoriatic arthritis	0.000167	0.0004	CbGpPWpGaD
Crizotinib—RIPK2—Innate Immune System—HLA-B—psoriatic arthritis	0.000166	0.000398	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—HLA-C—psoriatic arthritis	0.000164	0.000392	CbGpPWpGaD
Crizotinib—PTK2—Innate Immune System—NOD2—psoriatic arthritis	0.000162	0.000388	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—HLA-C—psoriatic arthritis	0.000162	0.000388	CbGpPWpGaD
Crizotinib—IKBKE—Immune System—HLA-B—psoriatic arthritis	0.000162	0.000387	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—HLA-C—psoriatic arthritis	0.000162	0.000386	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—HLA-C—psoriatic arthritis	0.000161	0.000386	CbGpPWpGaD
Crizotinib—JAK2—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	0.00016	0.000383	CbGpPWpGaD
Crizotinib—YES1—Innate Immune System—NOD2—psoriatic arthritis	0.00016	0.000383	CbGpPWpGaD
Crizotinib—RIPK2—Adaptive Immune System—HLA-B—psoriatic arthritis	0.00016	0.000382	CbGpPWpGaD
Crizotinib—FGR—Innate Immune System—HLA-B—psoriatic arthritis	0.000159	0.000381	CbGpPWpGaD
Crizotinib—BLK—Immune System—HLA-C—psoriatic arthritis	0.000158	0.000377	CbGpPWpGaD
Crizotinib—FGR—Immune System—HLA-C—psoriatic arthritis	0.000157	0.000376	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000156	0.000373	CbGpPWpGaD
Crizotinib—BLK—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000154	0.000368	CbGpPWpGaD
Crizotinib—IRAK1—Regulation of toll-like receptor signaling pathway—TNF—psoriatic arthritis	0.000153	0.000365	CbGpPWpGaD
Crizotinib—NTRK1—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	0.000152	0.000364	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—HLA-C—psoriatic arthritis	0.000152	0.000363	CbGpPWpGaD
Crizotinib—IRAK1—Innate Immune System—NOD2—psoriatic arthritis	0.000152	0.000363	CbGpPWpGaD
Crizotinib—LCK—Immune System—MEFV—psoriatic arthritis	0.000151	0.000362	CbGpPWpGaD
Crizotinib—PTK2—Apoptosis—TNF—psoriatic arthritis	0.000149	0.000358	CbGpPWpGaD
Crizotinib—TBK1—Immune System—NOD2—psoriatic arthritis	0.000149	0.000358	CbGpPWpGaD
Crizotinib—MET—Developmental Biology—TNF—psoriatic arthritis	0.000148	0.000354	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—NOD2—psoriatic arthritis	0.000147	0.000353	CbGpPWpGaD
Crizotinib—MAPK7—Immune System—HLA-B—psoriatic arthritis	0.000147	0.000352	CbGpPWpGaD
Crizotinib—LIMK1—Immune System—HLA-B—psoriatic arthritis	0.000147	0.000352	CbGpPWpGaD
Crizotinib—RIPK2—Innate Immune System—CRP—psoriatic arthritis	0.000147	0.000352	CbGpPWpGaD
Crizotinib—LYN—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.000145	0.000347	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—NOD2—psoriatic arthritis	0.000143	0.000343	CbGpPWpGaD
Crizotinib—IKBKE—Immune System—CRP—psoriatic arthritis	0.000143	0.000342	CbGpPWpGaD
Crizotinib—FGR—Hemostasis—NOS2—psoriatic arthritis	0.000143	0.000342	CbGpPWpGaD
Crizotinib—FGR—Innate Immune System—CRP—psoriatic arthritis	0.000141	0.000337	CbGpPWpGaD
Crizotinib—LCK—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	0.00014	0.000336	CbGpPWpGaD
Crizotinib—PTK2—Immune System—REL—psoriatic arthritis	0.00014	0.000334	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—REL—psoriatic arthritis	0.000139	0.000332	CbGpPWpGaD
Crizotinib—YES1—Immune System—REL—psoriatic arthritis	0.000138	0.00033	CbGpPWpGaD
Crizotinib—IKBKE—Immune System—HLA-DRB1—psoriatic arthritis	0.000137	0.000327	CbGpPWpGaD
Crizotinib—JAK2—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.000136	0.000324	CbGpPWpGaD
Crizotinib—RIPK2—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	0.000135	0.000323	CbGpPWpGaD
Crizotinib—JAK3—Immune System—NOD2—psoriatic arthritis	0.000135	0.000323	CbGpPWpGaD
Crizotinib—SRC—Immune System—MEFV—psoriatic arthritis	0.000134	0.000321	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—HLA-C—psoriatic arthritis	0.000133	0.000318	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—REL—psoriatic arthritis	0.000131	0.000313	CbGpPWpGaD
Crizotinib—PTK2—Innate Immune System—HLA-B—psoriatic arthritis	0.00013	0.000312	CbGpPWpGaD
Crizotinib—BLK—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	0.00013	0.000311	CbGpPWpGaD
Crizotinib—LIMK1—Immune System—CRP—psoriatic arthritis	0.00013	0.000311	CbGpPWpGaD
Crizotinib—MAPK7—Immune System—CRP—psoriatic arthritis	0.00013	0.000311	CbGpPWpGaD
Crizotinib—FES—Developmental Biology—TNF—psoriatic arthritis	0.000129	0.000309	CbGpPWpGaD
Crizotinib—YES1—Innate Immune System—HLA-B—psoriatic arthritis	0.000129	0.000308	CbGpPWpGaD
Crizotinib—PTK2—Immune System—HLA-C—psoriatic arthritis	0.000129	0.000308	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000128	0.000306	CbGpPWpGaD
Crizotinib—TYK2—Immune System—REL—psoriatic arthritis	0.000127	0.000303	CbGpPWpGaD
Crizotinib—YES1—Immune System—HLA-C—psoriatic arthritis	0.000127	0.000303	CbGpPWpGaD
Crizotinib—LIMK1—Immune System—HLA-DRB1—psoriatic arthritis	0.000125	0.000298	CbGpPWpGaD
Crizotinib—MAPK7—Immune System—HLA-DRB1—psoriatic arthritis	0.000125	0.000298	CbGpPWpGaD
Crizotinib—YES1—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000124	0.000296	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—REL—psoriatic arthritis	0.000123	0.000294	CbGpPWpGaD
Crizotinib—EPHA5—Developmental Biology—TNF—psoriatic arthritis	0.000123	0.000293	CbGpPWpGaD
Crizotinib—EPHA3—Developmental Biology—TNF—psoriatic arthritis	0.000123	0.000293	CbGpPWpGaD
Crizotinib—ABL2—Developmental Biology—TNF—psoriatic arthritis	0.000123	0.000293	CbGpPWpGaD
Crizotinib—IRAK1—Innate Immune System—HLA-B—psoriatic arthritis	0.000122	0.000292	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—NOD2—psoriatic arthritis	0.00012	0.000288	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—HLA-C—psoriatic arthritis	0.00012	0.000288	CbGpPWpGaD
Crizotinib—TBK1—Immune System—HLA-B—psoriatic arthritis	0.00012	0.000287	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—NOD2—psoriatic arthritis	0.000119	0.000286	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—NOD2—psoriatic arthritis	0.000119	0.000284	CbGpPWpGaD
Crizotinib—LCK—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.000119	0.000284	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—NOD2—psoriatic arthritis	0.000119	0.000284	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—HLA-B—psoriatic arthritis	0.000118	0.000284	CbGpPWpGaD
Crizotinib—EPHA8—Developmental Biology—TNF—psoriatic arthritis	0.000118	0.000283	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—HLA-C—psoriatic arthritis	0.000118	0.000282	CbGpPWpGaD
Crizotinib—LIMK2—Developmental Biology—TNF—psoriatic arthritis	0.000117	0.00028	CbGpPWpGaD
Crizotinib—EPHA4—Developmental Biology—TNF—psoriatic arthritis	0.000117	0.00028	CbGpPWpGaD
Crizotinib—EPHB4—Developmental Biology—TNF—psoriatic arthritis	0.000117	0.00028	CbGpPWpGaD
Crizotinib—PTK2—Hemostasis—NOS2—psoriatic arthritis	0.000117	0.00028	CbGpPWpGaD
Crizotinib—TYK2—Immune System—HLA-C—psoriatic arthritis	0.000117	0.000279	CbGpPWpGaD
Crizotinib—BLK—Immune System—NOD2—psoriatic arthritis	0.000116	0.000277	CbGpPWpGaD
Crizotinib—FGR—Immune System—NOD2—psoriatic arthritis	0.000115	0.000276	CbGpPWpGaD
Crizotinib—PTK2—Innate Immune System—CRP—psoriatic arthritis	0.000115	0.000276	CbGpPWpGaD
Crizotinib—YES1—Hemostasis—NOS2—psoriatic arthritis	0.000115	0.000276	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—HLA-B—psoriatic arthritis	0.000115	0.000276	CbGpPWpGaD
Crizotinib—LIMK1—Developmental Biology—TNF—psoriatic arthritis	0.000114	0.000274	CbGpPWpGaD
Crizotinib—YES1—Innate Immune System—CRP—psoriatic arthritis	0.000114	0.000272	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000113	0.000271	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—NOD2—psoriatic arthritis	0.000112	0.000267	CbGpPWpGaD
Crizotinib—EPHB6—Developmental Biology—TNF—psoriatic arthritis	0.00011	0.000263	CbGpPWpGaD
Crizotinib—JAK3—Immune System—HLA-B—psoriatic arthritis	0.000109	0.00026	CbGpPWpGaD
Crizotinib—IRAK1—Innate Immune System—CRP—psoriatic arthritis	0.000108	0.000258	CbGpPWpGaD
Crizotinib—TBK1—Immune System—CRP—psoriatic arthritis	0.000106	0.000254	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—CRP—psoriatic arthritis	0.000105	0.000251	CbGpPWpGaD
Crizotinib—YES1—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	0.000105	0.00025	CbGpPWpGaD
Crizotinib—EPHA6—Developmental Biology—TNF—psoriatic arthritis	0.000103	0.000247	CbGpPWpGaD
Crizotinib—LYN—Immune System—REL—psoriatic arthritis	0.000103	0.000246	CbGpPWpGaD
Crizotinib—ABL1—Immune System—REL—psoriatic arthritis	0.000102	0.000245	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—CRP—psoriatic arthritis	0.000102	0.000244	CbGpPWpGaD
Crizotinib—TBK1—Immune System—HLA-DRB1—psoriatic arthritis	0.000102	0.000243	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—NOD2—psoriatic arthritis	9.78e-05	0.000234	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—HLA-DRB1—psoriatic arthritis	9.75e-05	0.000233	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—HLA-B—psoriatic arthritis	9.69e-05	0.000232	CbGpPWpGaD
Crizotinib—JAK2—Immune System—REL—psoriatic arthritis	9.61e-05	0.00023	CbGpPWpGaD
Crizotinib—JAK3—Immune System—CRP—psoriatic arthritis	9.61e-05	0.00023	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—HLA-B—psoriatic arthritis	9.6e-05	0.00023	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—HLA-B—psoriatic arthritis	9.55e-05	0.000229	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—HLA-B—psoriatic arthritis	9.55e-05	0.000228	CbGpPWpGaD
Crizotinib—EPHA2—Developmental Biology—TNF—psoriatic arthritis	9.53e-05	0.000228	CbGpPWpGaD
Crizotinib—PTK2—Immune System—NOD2—psoriatic arthritis	9.45e-05	0.000226	CbGpPWpGaD
Crizotinib—LYN—Immune System—HLA-C—psoriatic arthritis	9.45e-05	0.000226	CbGpPWpGaD
Crizotinib—ABL1—Immune System—HLA-C—psoriatic arthritis	9.41e-05	0.000225	CbGpPWpGaD
Crizotinib—YES1—Immune System—NOD2—psoriatic arthritis	9.32e-05	0.000223	CbGpPWpGaD
Crizotinib—BLK—Immune System—HLA-B—psoriatic arthritis	9.32e-05	0.000223	CbGpPWpGaD
Crizotinib—FGR—Immune System—HLA-B—psoriatic arthritis	9.29e-05	0.000222	CbGpPWpGaD
Crizotinib—ABL1—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	9.25e-05	0.000221	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—HLA-B—psoriatic arthritis	9.21e-05	0.00022	CbGpPWpGaD
Crizotinib—JAK3—Immune System—HLA-DRB1—psoriatic arthritis	9.2e-05	0.00022	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—HLA-B—psoriatic arthritis	8.98e-05	0.000215	CbGpPWpGaD
Crizotinib—JAK2—Immune System—HLA-C—psoriatic arthritis	8.84e-05	0.000212	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—NOD2—psoriatic arthritis	8.84e-05	0.000212	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—NOD2—psoriatic arthritis	8.66e-05	0.000207	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—NOS2—psoriatic arthritis	8.59e-05	0.000206	CbGpPWpGaD
Crizotinib—TYK2—Immune System—NOD2—psoriatic arthritis	8.58e-05	0.000205	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—CRP—psoriatic arthritis	8.56e-05	0.000205	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—NOS2—psoriatic arthritis	8.55e-05	0.000205	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—CRP—psoriatic arthritis	8.48e-05	0.000203	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—CRP—psoriatic arthritis	8.44e-05	0.000202	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—CRP—psoriatic arthritis	8.44e-05	0.000202	CbGpPWpGaD
Crizotinib—LCK—Immune System—REL—psoriatic arthritis	8.42e-05	0.000201	CbGpPWpGaD
Crizotinib—BLK—Immune System—CRP—psoriatic arthritis	8.24e-05	0.000197	CbGpPWpGaD
Crizotinib—FGR—Immune System—CRP—psoriatic arthritis	8.21e-05	0.000196	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—HLA-DRB1—psoriatic arthritis	8.2e-05	0.000196	CbGpPWpGaD
Crizotinib—ABCB1—Allograft Rejection—TNF—psoriatic arthritis	8.09e-05	0.000194	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—HLA-DRB1—psoriatic arthritis	8.08e-05	0.000193	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—NOS2—psoriatic arthritis	8.04e-05	0.000192	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—CRP—psoriatic arthritis	7.94e-05	0.00019	CbGpPWpGaD
Crizotinib—BLK—Immune System—HLA-DRB1—psoriatic arthritis	7.89e-05	0.000189	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—HLA-B—psoriatic arthritis	7.86e-05	0.000188	CbGpPWpGaD
Crizotinib—FGR—Immune System—HLA-DRB1—psoriatic arthritis	7.86e-05	0.000188	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	7.8e-05	0.000187	CbGpPWpGaD
Crizotinib—LCK—Immune System—HLA-C—psoriatic arthritis	7.75e-05	0.000185	CbGpPWpGaD
Crizotinib—PTK2—Immune System—HLA-B—psoriatic arthritis	7.6e-05	0.000182	CbGpPWpGaD
Crizotinib—CDK7—Disease—NOS2—psoriatic arthritis	7.56e-05	0.000181	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—HLA-B—psoriatic arthritis	7.55e-05	0.000181	CbGpPWpGaD
Crizotinib—YES1—Immune System—HLA-B—psoriatic arthritis	7.5e-05	0.000179	CbGpPWpGaD
Crizotinib—SRC—Immune System—REL—psoriatic arthritis	7.45e-05	0.000178	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—HLA-B—psoriatic arthritis	7.11e-05	0.00017	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—NOS2—psoriatic arthritis	7.04e-05	0.000168	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—HLA-B—psoriatic arthritis	6.96e-05	0.000167	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—CRP—psoriatic arthritis	6.95e-05	0.000166	CbGpPWpGaD
Crizotinib—LYN—Immune System—NOD2—psoriatic arthritis	6.95e-05	0.000166	CbGpPWpGaD
Crizotinib—ABL1—Immune System—NOD2—psoriatic arthritis	6.92e-05	0.000166	CbGpPWpGaD
Crizotinib—TYK2—Immune System—HLA-B—psoriatic arthritis	6.9e-05	0.000165	CbGpPWpGaD
Crizotinib—SRC—Immune System—HLA-C—psoriatic arthritis	6.86e-05	0.000164	CbGpPWpGaD
Crizotinib—SRC—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	6.75e-05	0.000161	CbGpPWpGaD
Crizotinib—PTK2—Immune System—CRP—psoriatic arthritis	6.72e-05	0.000161	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—HLA-B—psoriatic arthritis	6.69e-05	0.00016	CbGpPWpGaD
Crizotinib—YES1—Immune System—CRP—psoriatic arthritis	6.63e-05	0.000159	CbGpPWpGaD
Crizotinib—JAK2—Immune System—NOD2—psoriatic arthritis	6.5e-05	0.000156	CbGpPWpGaD
Crizotinib—PTK2—Immune System—HLA-DRB1—psoriatic arthritis	6.43e-05	0.000154	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	6.39e-05	0.000153	CbGpPWpGaD
Crizotinib—YES1—Immune System—HLA-DRB1—psoriatic arthritis	6.34e-05	0.000152	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—CRP—psoriatic arthritis	6.28e-05	0.00015	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—NOS2—psoriatic arthritis	6.23e-05	0.000149	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—CRP—psoriatic arthritis	6.15e-05	0.000147	CbGpPWpGaD
Crizotinib—TYK2—Immune System—CRP—psoriatic arthritis	6.1e-05	0.000146	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—HLA-DRB1—psoriatic arthritis	6.02e-05	0.000144	CbGpPWpGaD
Crizotinib—PTK2—Developmental Biology—TNF—psoriatic arthritis	5.91e-05	0.000141	CbGpPWpGaD
Crizotinib—TYK2—Immune System—HLA-DRB1—psoriatic arthritis	5.84e-05	0.00014	CbGpPWpGaD
Crizotinib—YES1—Developmental Biology—TNF—psoriatic arthritis	5.83e-05	0.00014	CbGpPWpGaD
Crizotinib—LCK—Immune System—NOD2—psoriatic arthritis	5.7e-05	0.000136	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	5.66e-05	0.000135	CbGpPWpGaD
Crizotinib—LYN—Immune System—HLA-B—psoriatic arthritis	5.59e-05	0.000134	CbGpPWpGaD
Crizotinib—ABL1—Immune System—HLA-B—psoriatic arthritis	5.56e-05	0.000133	CbGpPWpGaD
Crizotinib—TYK2—Developmental Biology—TNF—psoriatic arthritis	5.37e-05	0.000128	CbGpPWpGaD
Crizotinib—JAK2—Immune System—HLA-B—psoriatic arthritis	5.23e-05	0.000125	CbGpPWpGaD
Crizotinib—TYK2—Disease—NOS2—psoriatic arthritis	5.14e-05	0.000123	CbGpPWpGaD
Crizotinib—SRC—Immune System—NOD2—psoriatic arthritis	5.04e-05	0.000121	CbGpPWpGaD
Crizotinib—LYN—Immune System—CRP—psoriatic arthritis	4.94e-05	0.000118	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CRP—psoriatic arthritis	4.92e-05	0.000118	CbGpPWpGaD
Crizotinib—LYN—Immune System—HLA-DRB1—psoriatic arthritis	4.73e-05	0.000113	CbGpPWpGaD
Crizotinib—ABL1—Immune System—HLA-DRB1—psoriatic arthritis	4.71e-05	0.000113	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CRP—psoriatic arthritis	4.62e-05	0.000111	CbGpPWpGaD
Crizotinib—LCK—Immune System—HLA-B—psoriatic arthritis	4.58e-05	0.00011	CbGpPWpGaD
Crizotinib—JAK2—Immune System—HLA-DRB1—psoriatic arthritis	4.43e-05	0.000106	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—TNF—psoriatic arthritis	4.35e-05	0.000104	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—TNF—psoriatic arthritis	4.33e-05	0.000104	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—TNF—psoriatic arthritis	4.07e-05	9.73e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—HLA-B—psoriatic arthritis	4.06e-05	9.7e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CRP—psoriatic arthritis	4.05e-05	9.69e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	3.99e-05	9.55e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—NOS2—psoriatic arthritis	3.89e-05	9.31e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—HLA-DRB1—psoriatic arthritis	3.88e-05	9.28e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CRP—psoriatic arthritis	3.58e-05	8.58e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—HLA-DRB1—psoriatic arthritis	3.43e-05	8.21e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—NOS2—psoriatic arthritis	3.41e-05	8.16e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—TNF—psoriatic arthritis	3.15e-05	7.55e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—NOS2—psoriatic arthritis	3.02e-05	7.22e-05	CbGpPWpGaD
